Cargando…
Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
BACKGROUND: Immune checkpoint inhibitors can result in overlap syndrome comprised of myasthenia gravis, myositis and myocarditis. However, the mortality predictors have not been clearly delineated. METHODS: We examined the characteristics of 11 patients diagnosed with overlap syndrome at Cleveland C...
Autores principales: | Longinow, Joshua, Zmaili, Mohammad, Skoza, Warren, Kondoleon, Nicholas, Marquardt, Robert, Calabrese, Cassandra, Funchain, Pauline, Moudgil, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939107/ https://www.ncbi.nlm.nih.gov/pubmed/36128926 http://dx.doi.org/10.1002/cam4.5050 |
Ejemplares similares
-
Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit
por: Deharo, François, et al.
Publicado: (2022) -
Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)